Baimuxinal is an agarwood-linked sesquiterpenoid aldehyde identified from Aquilaria sinensis and repeatedly reported as a notable marker in Chinese agarwood extracts and oils. The strongest live evidence supports its identity, structure, and occurrence in agarwood chemistry rather than standalone human-use benefits or safety outcomes. For AromaForge, it is best described as an agarwood character and composition marker with limited constituent-specific pharmacology and clear evidence gaps.
Chemical identity and composition
PubChem resolves baimuxinal to CID 135215 with formula C15H24O2 and IUPAC name 3-(2-hydroxypropan-2-yl)-6-methylspiro[4.5]dec-9-ene-10-carbaldehyde. PubMed indexes the 1983 Acta Pharmaceutica Sinica paper that reported isolation and structure elucidation of baimuxinal from Aquilaria sinensis. Within the archive, agarwood oil already cites baimuxinal at 2.44% to 14.78%, and a 2024 CO2 extract paper reported baimuxinal at 1.90%, reinforcing its role as a recurrent agarwood marker constituent.
Aroma and practical use
- Use the recorded woody, resinous, agarwood-like, resin descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1983 Acta Pharmaceutica Sinica paper reported isolation and structure elucidation of two new sesquiterpenes from Aquilaria sinensis, including baimuxinal.
A 1983 Acta Pharmaceutica Sinica paper reported isolation and structure elucidation of two new sesquiterpenes from Aquilaria sinensis, including baimuxinal.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2011 Molecules comparison of chemically stimulated, wild, and healthy Aquilaria sinensis oils reported baimuxinal as a dominant component in stimulated and wild agarwood samples, including 14.78% in one chemically stimulated sample.
A 2011 Molecules comparison of chemically stimulated, wild, and healthy Aquilaria sinensis oils reported baimuxinal as a dominant component in stimulated and wild agarwood samples, including 14.78% in one chemically stimulated sample.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2024 Molecules paper on CO2 supercritical extract of infected Aquilaria sinensis reported baimuxinal at 1.90% among sesquiterpenic constituents typically found in agarwood essential oils.
A 2024 Molecules paper on CO2 supercritical extract of infected Aquilaria sinensis reported baimuxinal at 1.90% among sesquiterpenic constituents typically found in agarwood essential oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, human dermal study, or dedicated toxicology assessment was verified for isolated baimuxinal in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the located biological context is mainly mixture-level agarwood research, archive copy should avoid assigning antimicrobial or broader therapeutic effects to isolated baimuxinal.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
constituent marker in agarwood volatile profiles
The clearest supported role for baimuxinal in the reviewed literature is analytical: it recurs in GC-MS and extract profiles used to distinguish infected or induced agarwood materials.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- No human clinical evidence for isolated baimuxinal was verified in this pass.
- No direct constituent-specific safety monograph or dermal restriction was located.
- The accessible pharmacology evidence is mostly about agarwood mixtures rather than isolated baimuxinal.
- No constituent-specific IFRA limit or Tisserand & Young Essential Oil Safety monograph was located for baimuxinal (CAS 86408-21-1) as of 2026-07-13; targeted web searches and the IFRA Standards Index (51st Amendment) returned no listing for this material, so dermal_limit_pct remains unverified.
- Uncited placeholder values (dermal_limit_pct:5, sensitizing:true) removed on QA re-check 2026-07; no authoritative source found.
- 2026-07-13 second re-verification pass: searched ECHA C&L inventory (no substance-specific entry retrievable for CAS 86408-21-1) and lookchem/chemicalbook/echemi trade listings; these confirm identity/REACH pre-registration status only and provide no numeric dermal limit, GHS classification, or sensitization data. No Health Canada NHP monograph exists for this agarwood-specific sesquiterpenoid. dermal_limit_verified remains false; no numeric value set.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.